|
(Обзор литературы)
И.Б. Манухин, М.А. Геворкян, Г.Н.Минкина, Л.Б.Студеная
Кафедра акушерства и гинекологии лечебного факультета Московского Медицинского cтоматологического института
Проблемы репродукции, 4-1999, с.7-13
В начало...
(Окончание)
1. Сметник В.П.,Тумилович Л.Г. Неоперативная гинекология. М 1995;149-150.
2. Серов В.Н., Прилепская В.Н. и др. Гинекологическая эндокринология. М 1994;284-287.
3. Демидова И.Ю., Игнатова Н.Г., Рейдис И.М. Клин эндокринол 1998;1:3-27.
4. Кононенко И.В., Суркова Е.В., Анциферов М.Б. Метаболический синдром с позиции эндокринолога: что мы знаем и что мы уже можем сделать. Пробл эндокринол 1999;2:36-41.
5. Гинзбург Н.Н., Козупица Г.С. Значение распределения жира при ожирении. Пробл эндокринол 1996;6:30-33.
6. Сунцов Ю.И., Кудрякова С.В. Эпидемиология нарушенной толерантности к глюкозе. Пробл эндокринол 1999; 2:48-52.
7. Reaven G.M. Diabetes 1988; 37:1595-1607.
8. Burghen G.A., Givens J.R., Kitabchi A.Е. Сorrelation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50:113-116.
9. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333:853-861.
10. Dunaif A., Futterweit W. et al. Profound peripheral insulin resistance, independent of obesty, in the polycystic ovary syndrome. Diabetes 1989; 38:1165-1174.
11. Dunaif A., Scott D. et al. The insulin sensitizing agent Troglitazone: a novel therapy for the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81:3299-3306.
12. Dunaif A., Graf M. et al. Characterization of groups of hyperandrogenie women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia. J Clin Endocrinol Metab 1987; 65:499-507.
13. Dunaif A., Segal K. R. et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992; 41:1257-1266.
14. Nestler J.E. Role of hyperinsulinemia in the patogenesis of the polycystic ovary syndrome and its clinical implications. Sem Reprod Endocrinol 1997; 15(2):111-122.
15. Nestler J.E., Powers L P. et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991; 72:83-89.
16. Nestler J.E. Editorial. Sex homone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J Clin Endocrinol Metabol 1993; 76:273-274.
17. Nestler J.E., Clore J.N., Blackard W.C. Effects of insulin on steroidogenesis in vivo. In: Dunaif A., Civeru I. et al. Polycystic ovary syndrome. Cambridge: Blackwell scientific Publications 1992.
18. Nestler J.E., Jakubowicz D.J. et al. In the polycystic ovary syndrome insulin stimulate human thecal testosterone production via its own receptor by using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 1998; 80:2001-2005.
19. Nestler J.E., Barlascini C.O., Matt D.W. Suppression of serum insulin by diazoxide reduced serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027.
20. Nestler J.E., Jakubowicz D.J. Decreases in ovarian cytochrome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. Lancet 1990;336:900-903.
21. Wild R.A., Alaupovic P., Parker I.J. Lipid and apolipoprotein abnormalities in hirsute women. Am J Obstet Gynecol 1992;166:1191.
22. Wild R.A. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995; 98:27.
23. Waterworth D.M., Benett S.T. et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997;349:986-990.
24. Norman R.J., Masters S., Hague W. Hyperinsulinemia is common in family members of women with polycystic ovary syndrome. Fertil Steril 1996;66:942-947.
25. Willis D., Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the Type-1 insulin-like growth factor receptor. J Clin Endocrinol Metab 1995;80:3788-3790. 26. Ehrmann D.A., Bames R.B., Rosenfield R.T. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to gysregulation of androgen secretion. Endocrinol Rev 1995;16:322-353.
27. Ehrmann D.A., Sturis J. et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent mellitus. J Clin Invest 1995;96:520-527.
28. Dahlgren E., Johansson S. et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones. Fer-til Steril 1992;57:505-513.
29. Holte J., Bergh T. et al. Restored insulin sensitivity but persistenly increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995;80:2586-2593.
30. Talbott E., Guzick D. et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arter Throm vas Biol 1995;15:821-826.
31. Balen A.H., Conway G.S. et al. Polycystic ovary syndrome. The spectrum of the disorder in 1741 patients. Human Reprod 1995;10:2107-2111.
32. Kiddy D.S., Hamilton-Fairley D. et al. Improvement in endocrino and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol Oxf 1992;36:105-111.
33. Conway G.S.Polycystic ovary syndrome: clinical aspects. Baillieres Clin endocrinol Metab 1966;10:263-280.
34. Wild R.A.,Bartholomew M.J.The influence of body weigth on lipoprotein lipids on patients with polycystic ovary syndrome. Am J Obstet Gynecol 1988;159:423-427.
35. Scott J. New chapter for the fat controller. Nature 1996;379: 113-114.
36. Amiel S.A., Sherwin R.S. et al. Impaired insulin action in puberty. A contributing factor to poor glycemie control in adolescents with diabetes. N Engl J Med 1986;315:215-219. 37. Pasquali R., Venturoli S. et al. Insulin and C-peptide levels in obese patient with polycystic ovaries. Horm Metab Res 1982;14:284-287.
38. Zawadzki J.K., Dunaif A. Diagnostic criteria for polycystic ovary syndrome: toword a rational approach. Oxford, UK: Black-well Scientific 1992;377-384.
39. Haring H.U. Perspectives of the hyperinsulinemia/insulin resistance syndrome in NIDDM From Pathophysiology to Clinical Implications. Ed. E.Standl. Munchen 1990;3-13. 40. Bamett A.H. Hypertension Annual. 1992.
41. De Fronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-194.
42. Vague J., Bjontrop P. In: Vague P (ed) Metabolic Complications of Human Obesities. Amsterdam: Elsevier Scintific Publishers 1985;115-130.
43. Moller D.E., Flier J.S. Insulin resistance-mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-948. 44. Sampson M., Kong C. et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PA-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol Oxf 1996;45:623-629.
45. Zimmerman S., Phillips R.A. et al. Polycystic ovary syndrome: lack of hypertension despite insulin resistance. J Clin Endocrinol Metab 1992;75:508-513.
46. Andersen P., Seljeflot I. et al. Increasedinsulin sensitivas and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995;44:611- 616.
47. Holienbauch D.C., Pavek T.J. et al. Hyperglycemia impairs coronary microvascular endothelium-dependent vasodilation. Сirculation 1995;92:1-451.
48. Ehrman D.F., Schneider D.J. et al. Troglitazone improves defects in insulin action insulin secretion ovarian steroidogenesis and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116.
49. Knopp R.H., Zhu X.-D. et al. Sex hormones and lipid interactions: implications for cardiovascular disease in women. Endocrinology 1994;4:286-301.
50. Dahlgren E., Janson P.O. et al. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992;71:599-603.
51. Jakubowicz D.J., Nestler J.E. 17- -hydroxyprogesterone responses to leuprolide and serum androgens in obese women with polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1987;82:556-560.
52. Nestler J.E., Jakubowicz D.E. et al. Effect of metformin on spontaneous and clomiphen-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;336(2):1876-80. 53. Velazquez E.M., Mendoza S.et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-654.
54. Antonucci T., Whitcomb R. et al. Diabetes 1997;20(1):188-198.
Написать комментарий
| 
